Publications by authors named "Gourangie Gogoi"
J Family Med Prim Care
August 2024
Article Synopsis
- COVID-19, caused by the SARS-CoV-2 virus, led to rapid vaccine development like Covishield, but concerns about immunity and adverse events emerged.
- A study comparing IgG antibody levels and adverse events post-vaccination in seropositive vs. seronegative adults showed 61% were seropositive, with over half reporting minor adverse events, predominantly in younger females.
- The findings indicate that Covishield effectively induces an immune response, with seropositive individuals having higher antibody levels, and the observed adverse events were mostly minor, suggesting the vaccine is relatively safe.
